erlotinib hydrochloride has been researched along with lysine in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (lysine) | Trials (lysine) | Recent Studies (post-2010) (lysine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 37,449 | 622 | 11,213 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | lysine (IC50) |
|---|---|---|---|
| Cationic amino acid transporter 3 | Homo sapiens (human) | 158 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, X; Dohmae, N; Hamamoto, R; Kiyotani, K; Lingen, M; Matsuo, Y; Nakamura, Y; Park, JH; Saloura, V; Suzuki, T; Vougiouklakis, T; Zewde, M | 1 |
| Chen, JY; Ding, K; Gao, L; Lu, X; Ngan, SC; Sze, SK; Tang, G; Wang, W; Wang, X; Yao, SQ; Yuan, P | 1 |
2 other study(ies) available for erlotinib hydrochloride and lysine
| Article | Year |
|---|---|
WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.
Topics: Antineoplastic Agents; Biomarkers; Cell Nucleus; Cytoplasm; DNA Replication; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Head and Neck Neoplasms; Histone-Lysine N-Methyltransferase; Humans; Immunohistochemistry; Lysine; Methylation; Models, Biological; Nuclear Proteins; Proliferating Cell Nuclear Antigen; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Protein Transport | 2017 |
Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Lysine; Mammals; Protein Kinase Inhibitors | 2023 |